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Abstract: Introduction: Many procedures are available to manage cartilage defects of the talus,
including microfracturing (MFx) and Autologous Matrix Induced Chondrogenesis (AMIC). Whether
AMIC or MFx are equivalent for borderline sized defects of the talar shoulder is unclear. Thus, the
present study compared the efficacy of primary isolated AMIC versus MFx for borderline sized
focal unipolar chondral defects of the talar shoulder at midterm follow-up. Methods: Patients
undergoing primary isolated AMIC or MFx for focal unipolar borderline sized chondral defects of
the talar shoulder were recruited prospectively. For those patients who underwent AMIC, a type
I/III collagen resorbable membrane was used. The outcomes of interest were: Visual Analogic Scale
(VAS), Tegner Activity Scale, American Orthopedic Foot and Ankle Score (AOFAS). The Magnetic
Resonance Observation of Cartilage Repair Tissue (MOCART) was assessed by a blinded radiologist,
who had not been involved in the clinical management of the patients. Data concerning complication
rate and additional procedures were also collected. Results: The mean follow-up was 43.5 months.
The mean age of the 70 patients at operation was 32.0 years, with a mean defect size of 2.7 cm2. The
mean length of hospitalization was shorter in the MFx cohort (p = 0.01). No difference was found
between the two cohorts in terms of length of prior surgery symptoms and follow-up, mean age and
BMI, sex and side, and defect size. At a mean follow-up of 43.5 months, the AOFAS (p = 0.03), VAS
(p = 0.003), and Tegner (p = 0.01) scores were greater in the AMIC group. No difference was found
in the MOCART score (p = 0.08). The AMIC group evidenced lower rates of reoperation (p = 0.008)
and failure (p = 0.003). Conclusion: At midterm follow-up, AMIC provides better results compared
to MFx.
Keywords: talus; ankle; chondral defect; autologous matrix induced chondrogenesis; AMIC; mi-
crofractures; management; surgery
1. Introduction
Focal chondral defects of the talar shoulder are common [1,2]. Given the limited self-
healing capability of cartilage, chondral defects are debilitating, often requiring surgical
management [3–5]. Isolated microfractures (MFx) are recommended for defects smaller
than 2.5 cm2 [6–10]. For bigger defects, several different surgical techniques have been
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described [11–14]. Osteochondral allo- or autograft transplantation (OAT) has been ex-
tensively performed as management of such chondral defects [15–17]. While autografts
require a harvest site, allografts are expensive and have greater risk of failure [18,19]. Au-
tologous chondrocyte implantation (ACI) has been widely used to address talar chondral
defects [20,21]. ACI is a two sessions surgery which requires the harvest of cells and exter-
nal chondrocytes expansion [22,23]. Autologous Matrix-Induced Chondrogenesis (AMIC)
has been recently introduced [2,24]. AMIC does not require a harvest site, cell expansion,
and is performed in a single surgical session [25,26]. AMIC is combined with MFx covering
the lesions with a resorbable membrane to stabilize the resulting blood clot [27,28]. Thus,
AMIC exploits the regenerative potential of bone marrow-derived mesenchymal stem cells
arising from the subchondral bone [25,29].
Whether AMIC performed better than MFx for borderline sized defects (2.2 to 2.8 cm2)
of the talar shoulder is unclear. The present study compared the efficacy of primary isolated
AMIC versus MFx for borderline sized focal unipolar chondral defects of the talar shoulder
at midterm follow-up. We hypothesized that AMIC provides better outcomes compared
to MFx.
2. Material and Methods
2.1. Patients Recruitment
The present study was performed according to Strengthening the Reporting of Obser-
vational Studies in Epidemiology: the STROBE Statement [30]. In our setting, for patients
with defect sized 2 to 3 cm2, both AMIC or isolated MFx were routinely performed. From
2012, patients undergoing primary isolated AMIC or MFx for focal unipolar borderline
sized chondral defects of the talar shoulder (Figure 1), were recruited and followed-up
prospectively. The inclusion criteria were: (1) symptomatic chondral defect of the talar
shoulder, (2) single focal defect sized 2 to 3 cm2, (3) MRI evidence, (4) patients able to
understand the nature of the treatment and the study. The exclusion criteria were: (1)
kissing lesions, (2) bilateral lesions, (3) multifocal lesions, (4) previous ankle surgeries, (5)
any bone disease, (6) any skeletal malformation, (7) any other relevant pathology that could
have influenced the study. Suitable patients were informed about the pros and cons of
both techniques, and were left free to decide their own procedure. The present study was
approved and registered by the ethic committee of the RWTH University of Aachen (project
ID EK 438-20), and conducted according to the principles expressed in the Declaration of
Helsinki. All patients were able to understand the nature of their treatment and provided
written consent to use their clinical and imaging data for research purposes.
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2.2. Surgical Technique
All the surgeries were performed by three surgeons (BR, MT, AD) in a highly stan-
dardized fashion. All the surgeons were well behind their learning curve and had no
preference on the surgical procedure. Briefly, the ankle was plantar flexed and a 2 mm
K-wire was drilled in the distal tibia and another one in the talus. A Hintermann spreader
(Integra LifeSciences, Plainsboro, NJ, USA) was used for joint distraction. Lesions were
arthroscopically approached through standard anterolateral and anteromedial portals, ac-
cording to the defect location shown on MRI. After identification of the defect, debridement
and curettage of the non-viable border of the chondral tissue surrounding the lesion was
performed until viable shoulder cartilage was reached. At this stage, the two surgical
techniques take two different turns. In the MFx group, microfractures of 4 mm depth were
arthroscopically performed into the defect. In the AMIC group, an arthroscopically-assisted
mini-arthrotomy approach was used. A malleolar osteotomy was performed if the defect
was not accessible by simple mini-arthrotomy. Microfractures of 4 mm depth were per-
formed into the defect using a 1.2- or 1.4-mm Kirschner wire under constant irrigation with
normosaline. If subchondral bone was not viable, this was debrided and substituted with
autologous cancellous bone graft harvested from the osteotomy site or from the ipsilateral
iliac crest. An aluminum template was trimmed according to the defect. A resorbable
porcine type I/III collagen was used in all patients (Chondro-Gide®, Geistlich Pharma AG,
Wolhusen, Switzerland). The membrane was trimmed according to the aluminum template
to be slightly undersized in relation to the defect to avoid displacement, and hydrated in
a saline solution. The membrane was placed into the lesion and secured with fibrin glue.
The stability of the membrane was checked by flexing and extending the ankle. When an
osteotomy was performed, it was fixed with two malleolar screws inserted through the
predrilled holes and the wound sutured in a standard fashion. The rehabilitation protocol
was performed according to that previously published [25].
2.3. Outcomes of Interest
Prior to surgery, the following data were recorded: age, gender, side, area of defect,
additional autologous spongiosa transplantation, BMI (Kg/m2), score, symptoms duration,
prior surgery, and length of the hospital stay. At the last follow-up, patients underwent
an MRI and subsequently were invited to answer the following questionnaires: Visual
Analogic Scale (VAS), Tegner Activity Scale, American Orthopedic Foot and Ankle Score
(AOFAS). The Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) was
assessed by a blinded radiologist, who had not been involved in the clinical management of
the patients. Data concerning complications (failure, revision, arthroplasty, delamination,
hypertrophy) and additional procedures were also collected. Failure was defined as
persistent pain that affected negatively the quality of life and limited participation in
recreational activities. For those patients who underwent a malleolar osteotomy, the
occurrence of screw removal was not considered as revision surgery.
The primary outcome of interest was to compare the outcomes at the last follow-up
between the AMIC and MFx group. The secondary outcome of interests was to compare
within AMIC the location of the lesion (medial vs. lateral), the effect of the bone grafting
(bone graft vs. no bone graft), and the approach (distraction vs. osteotomy).
2.4. Statistical Analysis
All statistical analyses were performed using the software IBM SPSS version 25.
Continuous data were analyzed using the mean difference (MD), while for dichotomic
data, the odd ratio (OR) effect measures. The confidence interval was set at 95% in all
the comparisons. The T-test and x2 tests were performed, respectively, with values of
p < 0.05 considered statistically significant. The confidence interval (CI) was set at 95% in
all comparisons.
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3. Results
3.1. Recruitment Procedure
A total of 122 patients were initially evaluated. Of them, 38 were not eligible: multiple
defects (N = 7), kissing lesions (N = 11), bilateral lesions (N = 2), previous ankle surgeries
(N = 11), skeletal malformation (N = 3), other (N = 4). This left 84 patients: 63 AMIC and
21 MFx. A further 14 patients were lost to follow-up: 11 patients in the AMIC group, and 3
in the MFx group did not wish to further participate in the study for geographical reasons,
but they declared themselves satisfied on telephone interviews. Eventually, 70 patients
took part in the present study: 52 in the AMIC group and 18 in the MFx (Figure 2).
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3.2. Patients Demographics
The mean follow-up was 43.5 months. The mean age of the 70 patients on admission
was 32.0 years, with a mean defect size of 2.7 cm2, 44% (31 of 70 patients) were women,
and in 53% (37 of 70) of patients the right side was involved. The mean symptoms duration
before surgery was 45.8 months. The mean length of hospitalization was shorter in the
MFx cohort (p = 0.01). No other difference was found between the two cohorts in terms of
length of prior surgery symptoms and follow-up, mean age and BMI, sex and side, and
defect size (Table 1).
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Table 1. Demographic data of the patients (n.s.: not significant; AMIC: Autologous Matrix Induced
Chondrogenesis; MFx: Microfracures; BMI: Body Mass Index).
Endpoint AMIC (n = 52) MFx (n = 18) p
Follow-up (months) 44.2 ± 19.9 41.5 ± 18.1 n.s.
Mean age 31.5 ± 2.1 33.3 ± 6.2 n.s.
Sex (female) 44% (23 of 52) 44% (8 of 18) n.s.
Right ankle 52% (27 of 52) 56% (10 of 18) n.s.
Articular side (talus)
medial 60% (31 of 52) 72% (13 of 18) n.s.
lateral 40% (21 of 52) 18% (5 of 18) n.s.
Cancellous bone grafting (n) 39% (20 of 52)
from osteotomy site 14% (7 of 52)
from iliac crest 25% (13 of 52)
Approach
Malleolar osteotomy (n) 44% (23 of 52)
Distraction (n) 56% (29 of 52)
Symptom duration (months) 48.1 ± 80.7 39.3 ± 50.41 n.s.
Length of stay (days) 3.5 ± 1.6 1.9 ± 2.0 0.01
Area of defect (cm2) 2.8 ± 1.5 2.4 ± 0.4 n.s.
BMI (kg/m2) 27.1 ± 6.4 26.9 ± 3.8 n.s.
3.3. Outcomes of Interest
At a mean follow-up of 43.1 months, the AOFAS (p = 0.03), VAS (p = 0.003), and Tegner
(p = 0.01) scores were greater in the AMIC group. No difference was found in the MOCART
score (p = 0.08) (Table 2).
Table 2. Results of scores (AMIC: Autologous Matrix Induced Chondrogenesis; MFx: Microfracures;
VAS: Visual Analogue Scale; AOFAS: American Orthopedic Foot and Ankle Score; MOCART: Mag-
netic Resonance Observation of Cartilage Repair Tissue).
Endpoint AMIC (n = 52) MFx (n = 18) MD 95% CI p
MOCART 80.0 ± 25.4 66.8 ± 33.1 13.2 −1.822 to 28.222 0.08
AOFAS 83.8 ± 12.4 75.0 ± 19.3 8.8 0.921 to 16.679 0.03
VAS (0–10) 1.9 ± 0.8 3.3 ± 3.1 1.4 −2.326 to −0.474 0.003
Tegner 4.3 ± 1.5 3.1 ± 2.1 1.2 0.288 to 2.112 0.01
3.4. Complications
The AMIC group experienced lower rates of reoperation (p = 0.008) and failure
(p = 0.003). No hypertrophy or delamination were observed during follow-up (Table 3).
Five patients (10%) underwent revision surgery for persistent pain within four years post-
operatively in the AMIC group, seven (39%) in the MFx group. No complications related
to the bone harvest site were experienced by any patient.
Table 3. Complications.
Endpoint AMIC (n = 52) MFx (n = 18) OR 95% CI p
Reoperation 10% (5 of 52) 39% (7 of 18) 0.17 0.0446 to 0.6271 0.008
Failures 13% (7 of 52) 50% (9 of 18) 0.16 0.0459 to 0.5268 0.003
3.5. Subgroup Analysis
Within AMIC, no difference was evidenced by the subgroup analysis medial vs. lateral
lesions (p = 0.08), bone grafting vs. no-bone grafting (p = 0.09), and between joint distractors
vs. malleolar osteotomy (p = 0.07).
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4. Discussion
According to the main findings of the present study, AMIC performed better than
MFx at midterm follow-up. AOFAS and VAS both scored better in the AMIC group, along
with a greater sporting activity, according to the Tegner score. The rate of reoperation and
failure was also lower in the AMIC group at midterm follow-up. No complications related
to the harvest site were reported. Within the AMIC group, no difference was evidenced by
the subgroup analyses medial vs. lateral lesions, bone grafting vs. no-bone grafting, and
joint distractors vs. malleolar osteotomy.
Symptomatic chondral defects negatively affect the activities of daily life and sporting
activity level [25,31]. The low metabolic activity of hyaline cartilage, along with its alym-
phatic and hypocellular structure, are some of the reasons behind its poor regenerative
capabilities [3–5]. Cartilage healing typically does not restore the original tissue, and
fibrosis and residual chondral defects are common [32,33]. This impairs the cartilage biome-
chanical proprieties and predisposes to chronic pain [34,35]. AMIC has been successfully
used to address chondral defects of the talus, with a growing trend of clinical studies in the
current literature [36–38].
Only the study by Becher et al. [39] compared primary AMIC (N = 16) versus MFx
(N = 16) for talar defects in a retrospective fashion; both techniques produced similar
outcomes at five years follow-up. However, their patients had a mean defect smaller than
2 cm2 [39]. Chung et al. [40] compared AMIC versus MFx in 64 patients for knee chondral
defects. They included patients with a mean defect size of 1.3 cm2 in the AMIC group
and 1.5 cm2 in the MFx group, evidencing similarity between the two groups at two years
follow-up. Both these studies were performed in a cohort of patients with small defects.
Indeed, for small defects, MFx is still the most appropriate procedure [3–5,9]. Furthermore,
the relatively short length of the follow-up may also affect the results. In the present study,
we included only patients with borderline-sized defect (mean 2.7 cm2). We were unable
to identify further studies that compare AMIC vs. MFx for talus chondral defects of this
size. A similar study on chondral defects of the knee was performed by Volz et al. [41].
They compared AMIC versus MFx at five years in 47 patients with a mean defect size of
3.6 cm2. Similarly, they found a significant greater value of the Cincinnati score and lower
pain level in the AMIC cohort.
We used plantar flexion and Hintermann spreader to distract the tibiotalar joint as
standard, whereas, for lesions placed dorsally, a malleolar osteotomy was performed.
Malleolar osteotomy leads to possible bony complications, intraoperative cartilage damage,
loss of osteotomy reduction, delayed union or nonunion, persistent pain and/or swelling
at the osteotomy site, painful hardware requiring surgical revision [42,43]. The osteotomy
might damage the articular facet, and, given the poor regenerative capabilities of hyaline
cartilage, this may lead to pain and early osteoarthrosis of the tibiotalar joint. Plantar flexion
and Hintermann spreader to distract the tibiotalar allows patients to faster full bearing
and recovery, but it may predispose to soft tissue damage, especially the neurovascular
structures [44]. Indeed, in ankle arthroscopy series with mechanical distraction, the average
complication rate ranges between 8 and 17% [45–50], while in a series of 1305 consecutive
procedures with only plantar flexion the rate of complication was 3.4% [51]. In a cadaveric
study, de Leeuw et al. [52] demonstrated greater distance between the anterior distal tibia
and the overlying anterior neurovascular bundle with the ankle in a dorsiflexed position
compared to the distracted ankle position. Whether plantar flexion and Hintermann
spreader perform better than malleolar osteotomy is still controversial, and future studies
are required.
The relatively small number of patients included in the present investigation rep-
resents the most important limitation of the present study, and may affect the ability to
identify uncommon complications. The unblinded design, along with the lack of random-
ization, are two important limitations of the study. Further larger randomized controlled
trials are required. We emphasize, however, that randomization and blinding in surgery
may not be easily acceptable to patients and surgeons alike. The MOCART score was used
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to assess the degree of cartilage regeneration [53], but MRI is not reliable in predicting
clinical outcome after cartilage repair is uncertain [54–56]. During the time elapsed between
the onset of symptoms and the index surgery, all the patients underwent conservative
management. However, given the heterogeneous nature and/or the lack of documentation
of these treatments, it was not possible to analyze them separately. Similarly, most of the
15 patients who underwent revision surgeries were not aware of the treatment and/or data
were lacking; thus, no further analyses were possible.
5. Conclusions
The present study confirmed our hypothesis that AMIC demonstrated superiority
over MFx in focal osteochondral lesions of the talus between 2 and 3 cm2. At midterm
follow-up, AOFAS and VAS scores were both better in the AMIC group, along with a
greater sporting activity, according to the Tegner score. The rate of reoperation and failure
was also lower in the AMIC group.
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